Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (21.6), the stock would be worth ¥40.07 (40% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 36.1 | ¥66.8 |
0%
|
| 3-Year Average | 21.6 | ¥40.07 |
-40%
|
| 5-Year Average | 21.1 | ¥38.97 |
-42%
|
| Industry Average | 23.8 | ¥44.01 |
-34%
|
| Country Average | 20.8 | ¥38.53 |
-42%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
|
11.8B CNY | 36.1 | 51.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 53.3 | 41.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 23.7 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 14.7 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 21.8 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 15.5 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 19.1 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 17 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 10.7 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Chengdu Easton Biopharmaceuticals Co Ltd
Glance View
Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemical raw materials and chemical drug preparations. The company is headquartered in Chengdu, Sichuan and currently employs 1,188 full-time employees. The company went IPO on 2020-09-02. The firm's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The firm operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.
